Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | PTPN22 | Q9Y2R2 | 2/20 | 0.65 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.63 |
| ▸ | EIF4E | P06730 | 1/20 | 0.60 |
| ▸ | EIF4G1 | Q04637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897115 | 1.00 | MAPT (0.69) | MAPTPTPN22APEX1MAP3K5EIF4E | |
| SCHEMBL5164951 | 0.90 | PTPN22 (0.65) | MAPTPTPN22APEX1MAP3K5 | |
| SCHEMBL5164957 | 0.90 | PTPN22 (0.65) | MAPTPTPN22APEX1MAP3K5 | |
| SCHEMBL3894146 | 0.88 | STAT3 (0.60) | MAPTPTPN22MAP3K5EIF4EEIF4G1 | |
| SCHEMBL3894155 | 0.88 | STAT3 (0.60) | MAPTPTPN22MAP3K5EIF4EEIF4G1 | |
| SCHEMBL7859580 | 0.88 | MAPT (0.77) | MAPTPTPN22APEX1MAP3K5EIF4E | |
| SCHEMBL3905933 | 0.88 | MAPT (0.77) | MAPTPTPN22APEX1MAP3K5EIF4E | |
| SCHEMBL3904248 | 0.88 | MAPT (0.77) | MAPTPTPN22APEX1MAP3K5EIF4E | |
| SCHEMBL3896088 | 0.88 | PTPN22 (0.65) | MAPTPTPN22APEX1MAP3K5 | |
| SCHEMBL5145019 | 0.88 | PTPN22 (0.65) | MAPTPTPN22APEX1MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | MAPT 1187/4885PTPN22 3961/4885APEX1 1572/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | MAPT 880/4885PTPN22 3667/4885APEX1 888/4885 |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MAPT 2096/4885PTPN22 1167/4885APEX1 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.